New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
06:53 EDTFRXForest Labs acquisition positive, says Cantor
After Forest Labs agreed to buy Aptalis, a privately held company that focuses on gastrointestinal disease and cystic fibrosis, Cantor thinks that Aptalis is a good strategic fit for Forest Labs. The firm sees opportunities for revenue and cost synergies from the deal, and it raised its price target on Forest to $90 from $79 while keeping a Buy rating on the stock.
News For FRX From The Last 14 Days
Check below for free stories on FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
16:08 EDTFRXActavis, Forest Labs receive second request under Hart-Scott-Rodino from FTC
Subscribe for More Information
April 9, 2014
05:50 EDTFRXForest Labs reports FDA provided feedback on combination aclidinium, formoterol
Forest Laboratories announced that they have recently received feedback from the FDA regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC, or Chemistry, Manufacturing and Control, and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use